Switching from Eliquis (Apixaban) to Aspirin: A High-Risk Decision
Do not switch from apixaban to aspirin for atrial fibrillation—this significantly increases stroke risk while providing no meaningful bleeding benefit. The 2024 ESC Guidelines explicitly state that antiplatelet drugs like aspirin are not an alternative to oral anticoagulation and should not be used for stroke prevention in AF, as they can lead to potential harm 1.
The Evidence Against Switching
Stroke Prevention: Apixaban is Dramatically Superior
The AVERROES trial definitively demonstrated that apixaban reduces stroke or systemic embolism by 55% compared to aspirin (HR 0.45; 95% CI 0.32-0.62; P<0.001), with stroke rates of 1.6%/year versus 3.7%/year 2. This translates to preventing approximately 2 strokes per 100 patients per year—a clinically massive benefit.
In the FDA-approved ARISTOTLE trial, apixaban demonstrated superiority over warfarin for stroke prevention 3, and since aspirin is inferior to warfarin, the hierarchy is clear: apixaban > warfarin > aspirin.
The Bleeding Risk Myth
A critical misconception is that aspirin is "safer" than apixaban regarding bleeding—this is false.
- In AVERROES, major bleeding rates were nearly identical: 1.4%/year with apixaban versus 1.2%/year with aspirin 2
- Intracranial bleeding was similar: 11 cases with apixaban versus 13 with aspirin 1
- A 2025 meta-analysis confirmed intracranial hemorrhage risk with apixaban versus aspirin was comparable (relative risk 0.67; 95% CI 0.43-1.08) 4
The 2024 ESC Guidelines emphasize that combining antiplatelet drugs with anticoagulants increases bleeding without clear benefit, but switching FROM anticoagulation TO aspirin removes stroke protection while maintaining bleeding risk 1.
Clinical Context Matters
When Patients Are Already on Apixaban
If a patient is tolerating apixaban without bleeding complications, switching to aspirin:
- Increases annual stroke risk by approximately 2% (from 1.6% to 3.7%)
- Does NOT meaningfully reduce bleeding risk
- Violates guideline recommendations 1
Special Populations
For patients with prior stroke/TIA: The ARTESiA subgroup analysis showed that in patients with subclinical AF and prior stroke/TIA, apixaban prevented 7% absolute stroke risk over 3.5 years versus only 1% in those without prior stroke 5. Switching these high-risk patients to aspirin would be particularly dangerous.
For patients with high CHA₂DS₂-VASc scores (>4): Apixaban prevents 1.28 strokes per 100 patient-years while causing only 0.68 additional major bleeds 6. The benefit-risk ratio strongly favors continuing apixaban.
The Only Legitimate Reasons to Consider This Switch
- Active major bleeding that cannot be managed and is life-threatening
- Absolute contraindication to anticoagulation develops (e.g., recent intracranial hemorrhage, active bleeding disorder)
- Patient refusal of anticoagulation after thorough counseling about risks
Even in these scenarios, aspirin is not a substitute—it's a last resort with inferior efficacy 1.
Common Pitfalls to Avoid
- Don't switch due to minor bleeding (e.g., epistaxis, bruising)—these can often be managed without stopping anticoagulation
- Don't switch based on age alone—elderly patients benefit from apixaban and have similar relative bleeding risks 7
- Don't switch during the transition period—if switching is absolutely necessary, there's an initial 60-day period of increased risk 8
- Avoid NSAID use with either agent, as this dramatically increases bleeding risk (HR 10.25 in ARTESiA) 9
The Bottom Line
The risk-benefit calculation overwhelmingly favors continuing apixaban over switching to aspirin for atrial fibrillation. Apixaban prevents approximately 2 strokes per 100 patient-years compared to aspirin, with essentially equivalent major bleeding rates and similar intracranial hemorrhage risk. The 2024 ESC Guidelines are unequivocal: antiplatelet drugs should not be used for stroke prevention in AF 1.
If bleeding concerns arise, address them through dose adjustment (if criteria met), bleeding source management, or medication reconciliation—but switching to aspirin sacrifices stroke protection without meaningful safety gains.